Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

Non small cell lung carcinoma (NSCLC) is the most frequently occurring histologic subtype of lung cancer and is the leading cause of cancer-related deaths worldwide. The purpose of this study is to assess adverse events and change in disease activity when Telisotuzumab Adizutecan (ABBV-400) is given in combination with a programmed cell death receptor 1 (PD1) immune checkpoint inhibitor to adult participants to treat NSCLC. Telisotuzumab Adizutecan (ABBV-400) and budigalimab are investigational drugs being developed for the treatment of NSCLC. This study will be divided into two stages, with

Trial Details

NCT ID
NCT06772623
Phase
PHASE1 / PHASE2
Sponsor
AbbVie
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Telisotuzumab Adizutecan
  • Budigalimab
  • Pembrolizumab
  • Carboplatin
  • Pemetrexed
  • Cisplatin
Locations (sample)
  • Phoenix, Arizona, United States|33.44838,-112.07404
  • Fullerton, California, United States|33.87029,-117.92534
  • Oxnard, California, United States|34.1975,-119.17705
  • Santa Monica, California, United States|34.01949,-118.49138
  • Aurora, Colorado, United States|39.72943,-104.83192

Key Eligibility Criteria

  • Must have histologically documented non-squamous (NSq) non small cell lung carcinoma (NSCLC) that is locally advanced or metastatic will be enrolle…
  • Must have measurable disease per response evaluation criteria in solid tumors (RECIST) v1.1.
  • For Part 1, participants must have had no more than 1 systemic therapy for advanced disease including platinum-based chemotherapy or an immune chec…
  • For Part 2, participants must have no prior systemic therapy for advanced disease, no known actionable genomic alteration.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →